FierceBiotech

Addition of VX-661 to KALYDECO® (ivacaftor) Improves Lung Function in People with CF Who Are Heterozygous for the F508del and G551D Mutations in 28-day Phase 2 Proof-of ...

Addition of VX-661 to KALYDECO® (ivacaftor) Improves Lung Function in People with CF Who Are Heterozygous for the F508del and G551D Mutations in 28-day Phase 2 Proof-of-Concept Study -Data provide ...
Nature

Addition of plerixafor to G-CSF is useful to achieve efficient collection even in very poor mobilizers: hope for patients with diminished hematopoietic function

In 2016, we performed a complementary analysis of data extracted from the Osmoz registry, that is, the population of ‘very poor mobilizers’ who had <5 PB CD34+ cells/μL at day 4 of the mobilization ...